Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avanos Medical (AVNS) EBIT (2016 - 2026)

Avanos Medical's EBIT history spans 13 years, with the latest figure at $2.5 million for Q4 2025.

  • On a quarterly basis, EBIT rose 100.6% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$61.6 million, a 84.45% increase, with the full-year FY2025 number at -$61.6 million, up 84.45% from a year prior.
  • EBIT hit $2.5 million in Q4 2025 for Avanos Medical, up from $100000.0 in the prior quarter.
  • Over the last five years, EBIT for AVNS hit a ceiling of $16.6 million in Q4 2022 and a floor of -$418.5 million in Q4 2024.
  • Historically, EBIT has averaged -$22.2 million across 5 years, with a median of $2.9 million in 2021.
  • Biggest five-year swings in EBIT: surged 3500.0% in 2021 and later plummeted 3836.61% in 2024.
  • Tracing AVNS's EBIT over 5 years: stood at -$22.4 million in 2021, then soared by 174.11% to $16.6 million in 2022, then tumbled by 32.53% to $11.2 million in 2023, then plummeted by 3836.61% to -$418.5 million in 2024, then surged by 100.6% to $2.5 million in 2025.
  • Business Quant data shows EBIT for AVNS at $2.5 million in Q4 2025, $100000.0 in Q3 2025, and -$74.5 million in Q2 2025.